Tiziana Life Sciences Completes Dosing in Phase 2a MS Trial; Topline Data Expected Late Q3/Early Q4 2026
TLSA is trading near its 52-week low of $1.04 (7.7% above the low) on light trading volume (0.4× avg).
Summary
Tiziana Life Sciences announced the completion of dosing for all patients in its Phase 2a clinical trial of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis, with topline data expected in late Q3/early Q4 2026.
Key Events · Product Development and Regulatory · TLSA
-
Last Patient Dosed in Phase 2a Trial
All patients in the INFORM-MS Phase 2a clinical trial for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis have received their first dose.
-
Topline Data Anticipated
Topline data from the trial is expected in late Q3/early Q4 of 2026 and will be presented at the ACTRIMS/ECTRIMS meeting in October 2026.
-
Trial Progress for Lead Candidate
This milestone advances the development of intranasal foralumab, the company's lead candidate, which is the only fully human anti-CD3 monoclonal antibody in clinical development delivered intranasally.
Analysis · TLSA · Life Sciences
This 6-K announces a critical operational milestone for Tiziana Life Sciences, confirming that all patients in its Phase 2a INFORM-MS trial for intranasal foralumab have received their first dose. This progress is vital for the company, especially following a recent 'going concern' warning, and sets the stage for the highly anticipated topline data readout in late Q3/early Q4 2026. The successful completion of dosing de-risks the trial timeline and maintains momentum for their lead candidate in a condition with limited treatment options.
At the time of this filing, TLSA was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.7M. The 52-week trading range was $1.04 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.